Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant IGF2
- Development stage
- Preclinical
- Lead developer
- Universidad de Chile
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant insulin-like growth factor 2 (rIGF2) is a protein-based therapeutic candidate being investigated for its neuroprotective and immunomodulatory effects in neurodegenerative diseases, particularly Parkinson's disease. It functions by activating IGF2 signaling pathways, which have been shown to reduce proinflammatory markers (such as TLR4), prevent mitochondrial dysfunction, and inhibit cell death induced by misfolded alpha-synuclein. In preclinical research, rIGF2 is used to reprogram macrophages, which are then adoptively transferred to mitigate neuroinflammation and motor deficits. This approach aims to address the chronic inflammatory response and dopaminergic neuron loss characteristic of Parkinson's disease.
- Other names
- recombinant insulin-like growth factor 2recombinant human IGF-II
02
Targets
IR-A (Insulin receptor isoform A)IR-B (Insulin receptor isoform B)IGF-1R (Insulin-like growth factor 1 receptor)IGF2R (Cation-independent mannose-6-phosphate receptor)IGFBP5 (Insulin-like growth factor-binding protein 5)
Beyond the preview
Go deeper on recombinant IGF2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant IGF2.